Earendil Labs announces initiation of a phase 1 study of a half-life extended novel anti-TL1A antibody

Earendil Labs Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Bispecific Antibodies for Autoimmune and Inflammatory Bowel Diseases